Intranasal Zavegepant for Migraine Meets Coprimary Regulatory Endpoints in Pivotal Phase 3 Trial
December 09, 2021

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

8 New Drugs Approved for Primary Care: Q3 2021
October 08, 2021

The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.

FDA Approves Oral CGRP Inhibitor Atogepant for Prevention of Episodic Migraine
October 01, 2021

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

Primary Care Physicians Face Barriers to Utilization of New Migraine Drugs
April 19, 2021

The uptake among primary care physicians of new migraine drugs has been hindered by 2 significant obstacles, a headache specialist explained to Patient Care Online.

The Migraine Research Renaissance and Where it is Headed: A PI Interview
March 10, 2021

New and highly specific migraine drugs have significantly changed the clinical landscape for patients. We talked with Peter McAllister, MD, about where the research goes next.

Two Cannabis Researchers Discuss their Studies on Pain and the Realm of Cannabinoid Investigation
February 19, 2021

Cannabis researchers Drs Carrie Cuttler and Rebecca Craft discuss their findings, their labs at WSU, their new research, and what makes this kind of research a challenge.

Impact of Inhaled Cannabis for Acute Pain: Analysis of a Unique Data Set
February 11, 2021

Research on pain relief from use of medical cannabis poses myriad challenges. Veteran researchers discuss 2 new studies based on a deep well of user data.

Treating Episodic Migraine Headaches: Evidence for Drug and Nondrug Therapies
February 03, 2021

Migraine headaches are a condition commonly seen in primary care. Here is a top-line look at the evidence for efficacy of the wide range of treatments available.

Oral CGRP Inhibitor Rimegepant Effective in Migraine Prevention, Study Finds
January 28, 2021

In a phase 2/3 study, nearly half of rimegepant-treated patients demonstrated ≥50% reduction in the number of moderate-to-severe migraine days per month

Opioids for Migraine Headache? It Depends
September 24, 2018

A family physician with expertise in headache treatment makes the case for appropriate use of opioids in some patients.